Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 69.4% to $1.12 during Monday's regul

Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-m

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing special

FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a

Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized aroun

Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent n

Urgent  Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent

Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative c

Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative c

Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis,

Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis,

Gainers Seer (NASDAQ:SEER) shares rose 32.1% to $2.14 during Monday's pre-market session. The m

$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon

Selection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhib

Selection highlights the clinical value potential of Cadrenal's first-in-class 12-lipoxygenase inhib

Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to

Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to

New high-value indication for Phase 3-ready asset with data intended to support clinical development

New high-value indication for Phase 3-ready asset with data intended to support clinical development

Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with

Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with

PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a la

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.04) per share which beat the an

PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a la

Cadrenal has completed its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration

FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 dat

HC Wainwright & Co. analyst Joseph Pantginis maintains Cadrenal Therapeutics (NASDAQ:CVKD) wi

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.41) per share which missed the

Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Ca

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing innovative treatme

PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing therap

Encouraging data for CAD-1005 in Phase 2 HIT Study  EOP2 scheduled for Q1 for top-priority indicatio

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) was the target of a significant decreas

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel t

Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a backgroun

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) was the target of a large growth in sho

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative the

SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a bioph

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause o

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.31) per share which beat the an

Acquisition significantly enhances the Company's pipeline by adding novel assets in acute and ch

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.87) per share which missed the